0001104659-26-025308
SEC filingCoherus Oncology, Inc. reported a net income of $168.0 million for fiscal year 2025, driven primarily by a $351.1 million net income from discontinued operations. However, the company's continuing operations generated a net loss of $183.1 million on net revenue of $42.2 million, with total costs and expenses of $223.3 million. The operating loss from continuing operations was $181.1 million, reflecting significant research and development expenses of $108.9 million and selling, general and administrative expenses of $100.6 million. The company's cash position decreased by $37.1 million during the year, ending with $103.3 million in cash, cash equivalents and restricted cash. The balance sheet shows total assets of $258.3 million and total liabilities of $197.3 million, resulting in stockholders' equity of $61.0 million.
Coherus Oncology reported a net income of $168.0 million for fiscal year 2025, which represents a significant positive result on the surface. However, this outcome was entirely driven by $351.1 million in net income from discontinued operations. The company's continuing operations generated a substantial net loss of $183.1 million on net revenue of $42.2 million. The operating loss from continuing operations was $181.1 million, reflecting the company's ongoing investment in research and development ($108.9 million) and selling, general and administrative expenses ($100.6 million). Cost of goods sold was $13.8 million, resulting in a gross profit of $28.4 million from continuing operations. The company reported basic and diluted earnings per share of $1.00, with weighted-average shares outstanding of 117.1 million.
The company reported net revenue of $42.2 million from continuing operations for fiscal year 2025. No segment breakdown or geographic mix was provided in the available data. The revenue figure represents the company's ongoing commercial operations after accounting for the impact of discontinued operations. The document does not provide comparative revenue figures from prior periods, so year-over-year growth analysis cannot be performed based on the provided data. The revenue appears to be generated from the company's remaining commercial products and services following the sale transactions referenced in Note 6.
The company achieved a gross margin of 67.3% on its continuing operations, calculated from net revenue of $42.2 million and cost of goods sold of $13.8 million. However, the company's operating margin was negative 429.1% due to the $181.1 million operating loss on $42.2 million of revenue. This reflects the company's substantial investment in research and development ($108.9 million) and selling, general and administrative expenses ($100.6 million). The net loss from continuing operations was $183.1 million, which includes $9.0 million in interest expense and $7.0 million in other income. The company reported no income tax provision for the period.
The company used $138.5 million in cash from operating activities despite reporting net income of $168.0 million, primarily due to significant non-cash gains from discontinued operations and changes in working capital. Investing activities provided $375.1 million in cash, largely from the sale transactions referenced in Note 6, while financing activities used $273.7 million in cash for debt repayments and other financing activities. The net result was a $37.1 million decrease in cash, ending with $103.3 million in cash, cash equivalents and restricted cash. The balance sheet shows total assets of $258.3 million, including $88.9 million in cash and cash equivalents and $83.2 million in marketable securities. Total liabilities were $197.3 million, including $228.2 million in convertible notes and $37.1 million in term loans. Stockholders' equity was $61.0 million.
The filing does not provide specific forward-looking guidance, management projections, or strategic priorities in the provided data. The document references Note 6 regarding sale transactions and discontinued operations, but the full context of these transactions and their implications for future operations is not detailed in the provided excerpts. The company's significant investment in research and development ($108.9 million) suggests continued focus on developing its oncology pipeline. The substantial debt levels ($228.2 million in convertible notes) and negative operating cash flow from continuing operations represent ongoing financial challenges that the company will need to address in future periods.